Deutsche Bank AG set a €96.00 ($101.05) price target on Sanofi SA (EPA:SAN) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the stock.

SAN has been the subject of several other research reports. Jefferies Group set a €80.00 ($84.21) target price on Sanofi SA and gave the stock a neutral rating in a research note on Thursday, August 4th. Berenberg Bank set a €92.00 ($96.84) target price on Sanofi SA and gave the stock a buy rating in a research note on Tuesday, November 1st. Sanford C. Bernstein set a €77.00 ($81.05) target price on Sanofi SA and gave the stock a neutral rating in a research note on Monday, October 31st. JPMorgan Chase & Co. reaffirmed a sell rating on shares of Sanofi SA in a research note on Tuesday, October 4th. Finally, Kepler Capital Markets set a €89.00 ($93.68) target price on Sanofi SA and gave the stock a buy rating in a research note on Thursday, August 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of €84.07 ($88.49).

Shares of Sanofi SA (EPA:SAN) opened at 74.93 on Wednesday. The stock’s 50 day moving average is €25.50 and its 200 day moving average is €25.74. Sanofi SA has a 12 month low of €62.50 and a 12 month high of €84.81. The firm has a market cap of €96.44 billion and a P/E ratio of 22.99.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the propert of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this news story can be read at http://www.dailypolitical.com/2016/12/01/sanofi-sa-san-given-a-96-00-price-target-by-deutsche-bank-ag-analysts.html.

About Sanofi SA

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.